Halozyme Therapeutics, a biotechnology company developing novel oncology and drug-delivery therapies, has named Michael LaBarre as Chief Scientific Officer. He succeeds Dr Michael Shepard, who was appointed a Research Fellow for the company.
The move broadens LaBarre's responsibilities to include research and development of early pipeline assets, in addition to his role managing product development and Enhanze platform partnerships.
LaBarre's career includes more than 20 years of biotech drug discovery and development experience.
Prior to joining Halozyme in 2008, he was Vice President of Product Development at Paramount BioSciences; Director of analytical and protein biochemistry, discovery research at Biogen Idec; and Director analytical and formulation sciences, research and development at IDEC Pharmaceuticals.
